Status:

COMPLETED

Butorphanol in Pain Following Ablation for Hepatic Tumor

Lead Sponsor:

Bibo Wang

Collaborating Sponsors:

Eastern Hepatobiliary Surgery Hospital

Conditions:

Visceral Pain

Microwave Ablation

Eligibility:

All Genders

20-75 years

Phase:

NA

Brief Summary

The objective of this investigation was to evaluate the influence of Butorphanol on postoperative pain mitigation in patients undergoing microwave ablation for hepatic tumor. Employing a rigorously de...

Eligibility Criteria

Inclusion

  • patients performing Microwave Ablation sign the informed consent

Exclusion

  • Patients with a body mass index \> 30 kg/m2 a history of depression opioid dependence poorly controlled hypertension (systolic blood pressure \> 180 mmHg) myocardial infarction severe liver disease significant abdominal pain before surgery patients with sensory system or language dysfunctions who could not cooperate to complete the scale pregnant women.

Key Trial Info

Start Date :

March 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 9 2023

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT06031129

Start Date

March 1 2023

End Date

August 9 2023

Last Update

September 11 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Jinling Hosipiatl

Nanjing, Jiangsu, China, 200000

Butorphanol in Pain Following Ablation for Hepatic Tumor | DecenTrialz